vs

Side-by-side financial comparison of Ballard Power Systems Inc. (BLDP) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $17.7M, roughly 1.1× Ballard Power Systems Inc.). Ballard Power Systems Inc. runs the higher net margin — 994.4% vs -177.4%, a 1171.8% gap on every dollar of revenue.

Ballard Power Systems Inc. is a developer and manufacturer of proton exchange membrane (PEM) fuel cell products for markets such as heavy-duty motive, portable power, material handling as well as engineering services. Ballard has designed and shipped over 400 MW of fuel cell products to date.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BLDP vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.1× larger
LAB
$19.6M
$17.7M
BLDP
Higher net margin
BLDP
BLDP
1171.8% more per $
BLDP
994.4%
-177.4%
LAB

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
BLDP
BLDP
LAB
LAB
Revenue
$17.7M
$19.6M
Net Profit
$176.5M
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
Net Margin
994.4%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLDP
BLDP
LAB
LAB
Q3 25
$17.7M
$19.6M
Q2 25
$21.8M
Q1 25
$40.8M
Q3 24
$-12.3M
$22.1M
Q2 24
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
BLDP
BLDP
LAB
LAB
Q3 25
$176.5M
$-34.7M
Q2 25
$-33.5M
Q1 25
$-26.0M
Q3 24
$-26.9M
Q2 24
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
BLDP
BLDP
LAB
LAB
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q3 24
156.5%
54.9%
Q2 24
46.1%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
BLDP
BLDP
LAB
LAB
Q3 25
-168.5%
Q2 25
-118.1%
Q1 25
-80.8%
Q3 24
-120.9%
Q2 24
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
BLDP
BLDP
LAB
LAB
Q3 25
994.4%
-177.4%
Q2 25
-153.7%
Q1 25
-63.8%
Q3 24
-122.0%
Q2 24
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
BLDP
BLDP
LAB
LAB
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLDP
BLDP
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
Total Assets
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLDP
BLDP
LAB
LAB
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
BLDP
BLDP
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
BLDP
BLDP
LAB
LAB
Q3 25
$399.7M
Q2 25
$424.5M
Q1 25
$454.6M
Q3 24
$489.3M
Q2 24
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
BLDP
BLDP
LAB
LAB
Q3 25
$539.6M
Q2 25
$557.0M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
BLDP
BLDP
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLDP
BLDP
LAB
LAB
Operating Cash FlowLast quarter
$5.7M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
0.03×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLDP
BLDP
LAB
LAB
Q3 25
$5.7M
$-22.2M
Q2 25
$-20.7M
Q1 25
$-30.3M
Q3 24
$-6.6M
$-27.9M
Q2 24
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
BLDP
BLDP
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
BLDP
BLDP
LAB
LAB
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
BLDP
BLDP
LAB
LAB
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%
Cash Conversion
BLDP
BLDP
LAB
LAB
Q3 25
0.03×
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Q4 23
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLDP
BLDP

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons